EP3615010A4 - Verfahren zur behandlung des dravet-syndroms - Google Patents

Verfahren zur behandlung des dravet-syndroms Download PDF

Info

Publication number
EP3615010A4
EP3615010A4 EP18791035.1A EP18791035A EP3615010A4 EP 3615010 A4 EP3615010 A4 EP 3615010A4 EP 18791035 A EP18791035 A EP 18791035A EP 3615010 A4 EP3615010 A4 EP 3615010A4
Authority
EP
European Patent Office
Prior art keywords
methods
dravet syndrome
treating dravet
treating
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18791035.1A
Other languages
English (en)
French (fr)
Other versions
EP3615010A1 (de
Inventor
Yuri MARICICH
Evan NEWBOLD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cavion LLC
Original Assignee
Cavion LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cavion LLC filed Critical Cavion LLC
Publication of EP3615010A1 publication Critical patent/EP3615010A1/de
Publication of EP3615010A4 publication Critical patent/EP3615010A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP18791035.1A 2017-04-26 2018-04-26 Verfahren zur behandlung des dravet-syndroms Pending EP3615010A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762490357P 2017-04-26 2017-04-26
PCT/US2018/029610 WO2018200844A1 (en) 2017-04-26 2018-04-26 Methods for treating dravet syndrome

Publications (2)

Publication Number Publication Date
EP3615010A1 EP3615010A1 (de) 2020-03-04
EP3615010A4 true EP3615010A4 (de) 2021-06-30

Family

ID=63920144

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18791035.1A Pending EP3615010A4 (de) 2017-04-26 2018-04-26 Verfahren zur behandlung des dravet-syndroms

Country Status (11)

Country Link
US (1) US20200163943A1 (de)
EP (1) EP3615010A4 (de)
JP (1) JP7326159B2 (de)
KR (1) KR102616994B1 (de)
CN (1) CN110799215A (de)
AU (1) AU2018260693B2 (de)
CA (1) CA3061712A1 (de)
IL (1) IL270137B2 (de)
RU (1) RU2767661C2 (de)
SG (2) SG10202111892XA (de)
WO (1) WO2018200844A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3364993T3 (fi) 2015-10-22 2023-01-13 Menetelmiä angelmanin oireyhtymän hoitamiseksi
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
AU2018221722B2 (en) 2017-02-15 2022-02-03 Cavion, Inc. Calcium channel inhibitors
SG11201909960UA (en) 2017-04-26 2019-11-28 Cavion Inc Methods for improving memory and cognition and for treating memory and cognitive disorders
KR20210087459A (ko) 2018-10-03 2021-07-12 카비온, 인코포레이티드 (r)-2-(4-이소프로필페닐)-n-(1-(5-(2,2,2-트리플루오로에톡시)피리딘-2-일)에틸)아세트아미드를 사용하는 본태성 진전 치료
US11400065B2 (en) 2019-03-01 2022-08-02 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
CN112353767A (zh) * 2020-11-16 2021-02-12 海南锦瑞制药有限公司 一种盐酸地尔硫卓和普瑞巴林组合物及其制备方法及其应用
KR20230121776A (ko) * 2020-12-16 2023-08-21 캄테크, 인크. 아마니타 무스카리아 화합물
MX2023013983A (es) * 2021-05-24 2023-12-12 Cavion Inc Metodo de tratamiento del temblor esencial.
KR20240046879A (ko) 2021-08-17 2024-04-11 한국과학기술원 Cav3.1 유전자를 표적으로 하는 안티센스 올리고뉴클레오타이드 및 그의 용도
IT202100023651A1 (it) * 2021-09-14 2023-03-14 Edilio Lancellotti Niaprazina per uso veterinario nel trattamento di disturbi del sistema nervoso centrale
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016203239A1 (en) * 2015-06-17 2016-12-22 GW Research Limited Use of cannabinoids in the treatment of epilepsy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5269761B2 (ja) 2006-04-12 2013-08-21 メルク・シャープ・アンド・ドーム・コーポレーション ピリジルアミドｔ型カルシウムチャンネルアンタゴニスト
US8377968B2 (en) * 2008-06-02 2013-02-19 Zalicus Pharmaceuticals, Ltd. N-piperidinyl acetamide derivatives as calcium channel blockers
US20130036482A1 (en) * 2010-01-29 2013-02-07 National University Corporation Okayama University Method for assessment of potential for development of dravet syndrome and use thereof
WO2012094615A2 (en) 2011-01-07 2012-07-12 Zenyaku Kogyo Kabushikikaisha Use of cav3.1 selective t-type calcium channel antagonists
US9351968B1 (en) * 2015-09-09 2016-05-31 Ovid Therapeutics Inc Methods of treating developmental disorders using pipradrol
FI3364993T3 (fi) * 2015-10-22 2023-01-13 Menetelmiä angelmanin oireyhtymän hoitamiseksi

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016203239A1 (en) * 2015-06-17 2016-12-22 GW Research Limited Use of cannabinoids in the treatment of epilepsy

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
IANNETTI P ET AL: "Addition of verapamil in the treatment of severe myoclonic epilepsy in infancy", EPILEPSY RESEARCH, vol. 85, no. 1, 1 July 2009 (2009-07-01), pages 89 - 95, XP026171452, ISSN: 0920-1211, [retrieved on 20090320], DOI: 10.1016/J.EPLEPSYRES.2009.02.014 *
IINUMA K ET AL: "Clinical efficacy of zonisamide in childhood epilepsy after long-term treatment: a postmarketing, multi-institutional survey", SEIZURE, BAILLIERE TINDALL, LONDON, GB, vol. 13, 1 December 2004 (2004-12-01), pages S34 - S39, XP004613926, ISSN: 1059-1311, DOI: 10.1016/J.SEIZURE.2004.04.003 *
KEENE D L ET AL: "FLUNARIZINE AS A SUPPLEMENTARY MEDICATION IN REFRACTORY CHILDHOOD EPILEPSY A DOUBLE-BLIND CROSSOVER STUDY", CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, vol. 16, no. 2, 1989, pages 191 - 193, XP002801434, ISSN: 0317-1671 *
SO-HEE EUN ET AL: "Comparative trial of low- and high-dose zonisamide as monotherapy for childhood epilepsy", SEIZURE, BAILLIERE TINDALL, LONDON, GB, vol. 20, no. 7, 1 April 2011 (2011-04-01), pages 558 - 563, XP028247499, ISSN: 1059-1311, [retrieved on 20110407], DOI: 10.1016/J.SEIZURE.2011.04.005 *

Also Published As

Publication number Publication date
CA3061712A1 (en) 2018-11-01
JP2020517708A (ja) 2020-06-18
IL270137A (de) 2019-12-31
CN110799215A (zh) 2020-02-14
AU2018260693A1 (en) 2019-11-14
SG10202111892XA (en) 2021-12-30
AU2018260693B2 (en) 2024-01-11
WO2018200844A1 (en) 2018-11-01
SG11201909963YA (en) 2019-11-28
KR20190139302A (ko) 2019-12-17
US20200163943A1 (en) 2020-05-28
RU2767661C2 (ru) 2022-03-18
RU2019137951A3 (de) 2021-08-20
JP7326159B2 (ja) 2023-08-15
IL270137B1 (en) 2023-12-01
RU2019137951A (ru) 2021-05-26
EP3615010A1 (de) 2020-03-04
KR102616994B1 (ko) 2023-12-26
IL270137B2 (en) 2024-04-01

Similar Documents

Publication Publication Date Title
EP3615010A4 (de) Verfahren zur behandlung des dravet-syndroms
EP3500289A4 (de) Verfahren zur behandlung von tracheobronchomalazie
EP3359677A4 (de) Zusammensetzungen und verfahren zur behandlung von fragiles-x-syndrom und assoziierter syndrome
EP3288382A4 (de) Verfahren zur behandlung von krebs
EP3220558A4 (de) Wiedergabeverfahren, wiedergabevorrichtung und programm
EP3307713A4 (de) Ezh2-hemmer zur behandlung von lymphomen
EP3340971A4 (de) Verfahren zur behandlung des lennox-gastaut-syndroms mit fenfluramin
EP3154566A4 (de) Verfahren und zusammensetzungen zur behandlung von geschwüren
EP3606962A4 (de) Verfahren zur behandlung von cd73hi-tumoren
EP3299697A4 (de) Entfeuchter
EP3270058A4 (de) Abgasbehandlungsvorrichtung
EP3217656A4 (de) Wiedergabeverfahren, wiedergabevorrichtung und programm
EP3556383A4 (de) Neuartiges verfahren zur behandlung von diabetes
EP3151588A4 (de) Positionsbestimmungsvorrichtung, audiovorrichtung, positionsbestimmungsverfahren und programm
EP3442538A4 (de) Behandlung von extrapyramidalem syndrom mit trapidil
EP3193903A4 (de) Zusammensetzungen und verfahren zur behandlung von akutem strahlungssystem
EP3565540A4 (de) Verfahren zur behandlung von herz-kreislauf-erkrankungen
EP3448365A4 (de) Verfahren zur behandlung von verstopfung
EP3256117A4 (de) Verfahren zur behandlung von neuroblastomen
EP3260862A4 (de) Verfahren zur unterdrückung von proteinadsorption
EP3609522A4 (de) Verfahren und verbindungen zur behandlung von diabetes
EP3351296A4 (de) Gasbehandlungsverfahren
EP3338618A4 (de) Verfahren zum waschen einer behandlungswerkzeughubunterlage
EP3285921A4 (de) Verfahren zur regenerierung von festen adsorptionsmitteln
EP3681536A4 (de) Behandlungsverfahren

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20191122

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: MARICICH, YURI

Inventor name: NEWBOLD, EVAN

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/00 20060101AFI20210216BHEP

Ipc: A61K 38/00 20060101ALI20210216BHEP

Ipc: A61P 25/08 20060101ALI20210216BHEP

Ipc: A61K 33/24 20190101ALI20210216BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20210528

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/00 20060101AFI20210521BHEP

Ipc: A61K 33/24 20190101ALI20210521BHEP

Ipc: A61K 38/00 20060101ALI20210521BHEP

Ipc: A61P 25/08 20060101ALI20210521BHEP

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230522

P02 Opt-out of the competence of the unified patent court (upc) changed

Effective date: 20230527

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031000000

Ipc: A61K0031440000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20230929

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/08 20060101ALI20230915BHEP

Ipc: A61K 38/00 20060101ALI20230915BHEP

Ipc: A61K 33/24 20190101ALI20230915BHEP

Ipc: A61K 31/44 20060101AFI20230915BHEP

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTC Intention to grant announced (deleted)
INTG Intention to grant announced

Effective date: 20240311